BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 26747896)

  • 1. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
    Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
    Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
    Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
    Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG; Pasillas MP; Kamps MP
    Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
    Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
    Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
    Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.
    Kawagoe H; Humphries RK; Blair A; Sutherland HJ; Hogge DE
    Leukemia; 1999 May; 13(5):687-98. PubMed ID: 10374871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.
    Garcia-Cuellar MP; Steger J; Füller E; Hetzner K; Slany RK
    Haematologica; 2015 Jul; 100(7):905-13. PubMed ID: 25911551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.
    Hess JL; Bittner CB; Zeisig DT; Bach C; Fuchs U; Borkhardt A; Frampton J; Slany RK
    Blood; 2006 Jul; 108(1):297-304. PubMed ID: 16507773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
    So CW; Karsunky H; Wong P; Weissman IL; Cleary ML
    Blood; 2004 Apr; 103(8):3192-9. PubMed ID: 15070702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
    Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
    Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
    Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.
    Rozovskaia T; Feinstein E; Mor O; Foa R; Blechman J; Nakamura T; Croce CM; Cimino G; Canaani E
    Oncogene; 2001 Feb; 20(7):874-8. PubMed ID: 11314021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
    Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
    Mian YA; Zeleznik-Le NJ
    Leuk Res; 2016 Jul; 46():51-60. PubMed ID: 27123834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
    Zeisig BB; Milne T; García-Cuéllar MP; Schreiner S; Martin ME; Fuchs U; Borkhardt A; Chanda SK; Walker J; Soden R; Hess JL; Slany RK
    Mol Cell Biol; 2004 Jan; 24(2):617-28. PubMed ID: 14701735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.